Susquehanna International Group, LLP Verona Pharma PLC Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$15.46 - $30.16 $2.82 Million - $5.49 Million	-182,100 Reduced 60.04%	121,200 $3.49 Million
Q2 2024 Aug 15, 2024	BUY	$11.48 - $17.02 $3.13 Million - $4.63 Million	272,300 Added 878.39%	303,300 $4.39 Million
Q1 2024 May 07, 2024	BUY	$15.3 - $20.24 $319,770 - $423,015	20,900 Added 206.93%	31,000 $498,000
Q4 2023 Feb 14, 2024	SELL	$11.94 - $20.47 $13,134 - $22,517	-1,100 Reduced 9.82%	10,100 $200,000
Q3 2023 Nov 14, 2023	SELL	$16.3 - $22.09 $355,340 - $481,562	-21,800 Reduced 66.06%	11,200 $182,000
Q2 2023 Aug 11, 2023	SELL	$19.41 - $23.43 $60,171 - $72,633	-3,100 Reduced 8.59%	33,000 $697,000
Q1 2023 May 16, 2023	SELL	$18.06 - $25.27 $442,469 - $619,115	-24,500 Reduced 40.43%	36,100 $724,000
Q4 2022 Feb 14, 2023	BUY	$9.84 - $26.13 $441,816 - $1.17 Million	44,900 Added 285.99%	60,600 $1.58 Million
Q3 2022 Nov 14, 2022	BUY	$4.14 - $13.59 $64,997 - $213,363	15,700 New	15,700 $160,000

166

68.7M

704K

685K

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.17B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.